- X4 Pharmaceuticals (NASDAQ:XFOR) announced on Thursday a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor, and optimizing its U.S. promotion of XOLREMDI, approved for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).
- As
X4 Pharmaceuticals shares fall on restructuring, layoffs
